mTOR regulates memory CD8 T-cell differentiation.

Authors:
Koichi Araki
Koichi Araki
Emory University School of Medicine
Atlanta | United States
Alexandra P Turner
Alexandra P Turner
Indiana University School of Medicine
United States
Virginia Oliva Shaffer
Virginia Oliva Shaffer
Emory University
United States
Shivaprakash Gangappa
Shivaprakash Gangappa
Emory University School of Medicine
United States
Susanne A Keller
Susanne A Keller
Cytos Biotechnology AG
Martin F Bachmann
Martin F Bachmann
Swiss Federal Institute of Technology
Switzerland
Christian P Larsen
Christian P Larsen
Emory University School of Medicine
United States
Rafi Ahmed
Rafi Ahmed
Emory University School of Medicine
United States

Nature 2009 Jul 21;460(7251):108-12. Epub 2009 Jun 21.

Emory Vaccine Center and Department of Microbiology and Immunology, Atlanta, Georgia, USA.

Memory CD8 T cells are a critical component of protective immunity, and inducing effective memory T-cell responses is a major goal of vaccines against chronic infections and tumours. Considerable effort has gone into designing vaccine regimens that will increase the magnitude of the memory response, but there has been minimal emphasis on developing strategies to improve the functional qualities of memory T cells. Here we show that mTOR (mammalian target of rapamycin, also known as FRAP1) is a major regulator of memory CD8 T-cell differentiation, and in contrast to what we expected, the immunosuppressive drug rapamycin has immunostimulatory effects on the generation of memory CD8 T cells. Treatment of mice with rapamycin following acute lymphocytic choriomeningitis virus infection enhanced not only the quantity but also the quality of virus-specific CD8 T cells. Similar effects were seen after immunization of mice with a vaccine based on non-replicating virus-like particles. In addition, rapamycin treatment also enhanced memory T-cell responses in non-human primates following vaccination with modified vaccinia virus Ankara. Rapamycin was effective during both the expansion and contraction phases of the T-cell response; during the expansion phase it increased the number of memory precursors, and during the contraction phase (effector to memory transition) it accelerated the memory T-cell differentiation program. Experiments using RNA interference to inhibit expression of mTOR, raptor (also known as 4932417H02Rik) or FKBP12 (also known as FKBP1A) in antigen-specific CD8 T cells showed that mTOR acts intrinsically through the mTORC1 (mTOR complex 1) pathway to regulate memory T-cell differentiation. Thus these studies identify a molecular pathway regulating memory formation and provide an effective strategy for improving the functional qualities of vaccine- or infection-induced memory T cells.
PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Source Status
http://dx.doi.org/10.1038/nature08155DOI ListingPossible
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710807PMCFound
July 2009
4 Reads

Similar Publications

Aberrant CD8+ T-cell responses and memory differentiation upon viral infection of an ataxia-telangiectasia mouse model driven by hyper-activated Akt and mTORC1 signaling.

Am J Pathol 2011 Jun;178(6):2740-51

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.

Immune system-related pathology is common in ataxia-telangiectasia (A-T) patients and mice that lack the protein kinase, A-T mutated (ATM). However, it has not been studied how ATM influences immune responses to a viral infection. Using the lymphocytic choriomeningitis virus (LCMV) infection model, we show that ATM(-/-) mice, despite having fewer naïve CD8⁺ T cells, effectively clear the virus. Read More

View Article
June 2011

The role of mTOR in memory CD8 T-cell differentiation.

Immunol Rev 2010 May;235(1):234-43

Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.

The mammalian target of rapamycin (mTOR) is an intracellular kinase that regulates cell growth and metabolism. Its specific inhibitor rapamycin is currently used in transplant recipients as an immunosuppressive drug to prevent allograft rejection. Studies have shown complex and diverse mechanisms for the immunosuppressive effects of rapamycin. Read More

View Article
May 2010

Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity.

J Immunol 2012 Apr 29;188(7):3080-7. Epub 2012 Feb 29.

Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

Vaccine strategies aimed at generating CD8(+) T cell memory responses are likely to show augmented efficacy against chronic challenges like tumor. The abundance in variety of memory CD8(+) T cells behooves development of vaccine strategies that generate distinct memory responses and evaluate them for tumor efficacy. In this study, we demonstrate the ability of a variety of rapamycin treatment regimens to regulate virus vaccination-induced CD8(+) T cell memory responses and tumor efficacy. Read More

View Article
April 2012

Mcl-1 regulates effector and memory CD8 T-cell differentiation during acute viral infection.

Virology 2016 Mar 6;490:75-82. Epub 2016 Feb 6.

Department of Pathobiological Sciences, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA. Electronic address:

Mcl-1, an anti-apoptotic member of Bcl-2 family maintains cell viability during clonal expansion of CD8 T cells, but the cell intrinsic role of Mcl-1 in contraction of effectors or the number of memory CD8 T cells is unknown. Mcl-1 levels decline during the contraction phase but rebound to high levels in memory CD8 T cells. Therefore, by overexpressing Mcl-1 in CD8 T cells we asked whether limiting levels of Mcl-1 promote contraction of effectors and constrain CD8 T-cell memory. Read More

View Article
March 2016